EyeGate Pharmaceuticals: Funding, Investors & Team (Sep 2026)
EyeGate Pharmaceuticals is a clinical-stage specialty pharmaceutical company that develops medicines to treat eye diseases using its non-invasive, iontophoretic drug-delivery system. It is developing a proprietary platform of medicines to treat diseases of the eye using its unique, non-invasive, iontophoretic drug-delivery system called EyeGate II. This proprietary technology platform is based on over 10-years of development at the Bascom Palmer Eye Institute at the University of Miami and has been tested extensively in both pre-clinical and human studies in Europe. Because of the human eye's special anatomy, effective delivery of medicines to treat chronic diseases in the mid and posterior segments of the eye is less than adequate. They believe the EyeGate II Delivery System will offer both physicians and patients an important new alternative in advancing the treatment of eye disease.
EyeGate Pharmaceuticals has raised $10.8M across 1 funding round on record, the most recent a Post-IPO Equity of $10.8M announced in Aug 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
EyeGate Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Aug 2021.
EyeGate Pharmaceuticals Funding Rounds
EyeGate Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
EyeGate Pharmaceuticals Funding Compared to Other Biotechnology Startups
EyeGate Pharmaceuticals' latest round of $10.8M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like EyeGate Pharmaceuticals in Biotechnology and Waltham
Companies Similar to EyeGate Pharmaceuticals
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
EyeGate Pharmaceuticals Funding FAQs
What does EyeGate Pharmaceuticals do?
EyeGate Pharmaceuticals is a clinical-stage specialty pharmaceutical company that develops medicines to treat eye diseases using its non-invasive, iontophoretic drug-delivery system. It is developing a proprietary platform of medicines to treat diseases of the eye using its unique, non-invasive, iontophoretic drug-delivery system called EyeGate II. This proprietary technology platform is based on over 10-years of development at the Bascom Palmer Eye Institute at the University of Miami and has been tested extensively in both pre-clinical and human studies in Europe. Because of the human eye's special anatomy, effective delivery of medicines to treat chronic diseases in the mid and posterior segments of the eye is less than adequate. They believe the EyeGate II Delivery System will offer both physicians and patients an important new alternative in advancing the treatment of eye disease.
How much funding has EyeGate Pharmaceuticals raised?
EyeGate Pharmaceuticals has raised $10.8M across 1 round on record. The most recent is a Post-IPO Equity of $10.8M announced in Aug 2021.
When did EyeGate Pharmaceuticals last raise funding?
EyeGate Pharmaceuticals' most recent funding round on record is a Post-IPO Equity of $10.8M, announced in Aug 2021.
Who is the CEO of EyeGate Pharmaceuticals?
Stephen From is listed as CEO at EyeGate Pharmaceuticals.
Where is EyeGate Pharmaceuticals headquartered?
EyeGate Pharmaceuticals is based in Waltham, Massachusetts, United States.
How many employees does EyeGate Pharmaceuticals have?
EyeGate Pharmaceuticals is in the 11-50 employee band.
How does EyeGate Pharmaceuticals' funding compare to other Biotechnology startups?
EyeGate Pharmaceuticals' latest round of $10.8M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's EyeGate Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for EyeGate Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.